![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLSCR3 |
Gene summary for PLSCR3 |
![]() |
Gene information | Species | Human | Gene symbol | PLSCR3 | Gene ID | 57048 |
Gene name | phospholipid scramblase 3 | |
Gene Alias | PLSCR3 | |
Cytomap | 17p13.1 | |
Gene Type | protein-coding | GO ID | GO:0001836 | UniProtAcc | Q9NRY6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57048 | PLSCR3 | LZE4T | Human | Esophagus | ESCC | 1.44e-22 | 4.66e-01 | 0.0811 |
57048 | PLSCR3 | LZE7T | Human | Esophagus | ESCC | 3.01e-10 | 4.31e-01 | 0.0667 |
57048 | PLSCR3 | LZE20T | Human | Esophagus | ESCC | 3.16e-03 | 1.42e-01 | 0.0662 |
57048 | PLSCR3 | LZE21D1 | Human | Esophagus | HGIN | 5.38e-03 | 2.97e-01 | 0.0632 |
57048 | PLSCR3 | LZE22D1 | Human | Esophagus | HGIN | 3.26e-02 | 1.43e-01 | 0.0595 |
57048 | PLSCR3 | LZE22T | Human | Esophagus | ESCC | 6.95e-12 | 6.30e-01 | 0.068 |
57048 | PLSCR3 | LZE24T | Human | Esophagus | ESCC | 8.26e-28 | 6.34e-01 | 0.0596 |
57048 | PLSCR3 | LZE21T | Human | Esophagus | ESCC | 1.16e-05 | 3.44e-01 | 0.0655 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001082119 | Esophagus | HGIN | regulation of mitochondrion organization | 42/2587 | 144/18723 | 1.20e-06 | 4.68e-05 | 42 |
GO:000863720 | Esophagus | HGIN | apoptotic mitochondrial changes | 33/2587 | 107/18723 | 4.32e-06 | 1.42e-04 | 33 |
GO:000183618 | Esophagus | HGIN | release of cytochrome c from mitochondria | 21/2587 | 59/18723 | 2.14e-05 | 5.72e-04 | 21 |
GO:00901998 | Esophagus | HGIN | regulation of release of cytochrome c from mitochondria | 18/2587 | 48/18723 | 3.67e-05 | 9.22e-04 | 18 |
GO:0010821110 | Esophagus | ESCC | regulation of mitochondrion organization | 107/8552 | 144/18723 | 2.31e-12 | 9.41e-11 | 107 |
GO:0008637110 | Esophagus | ESCC | apoptotic mitochondrial changes | 83/8552 | 107/18723 | 1.43e-11 | 5.08e-10 | 83 |
GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:000183619 | Esophagus | ESCC | release of cytochrome c from mitochondria | 47/8552 | 59/18723 | 9.02e-08 | 1.51e-06 | 47 |
GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
GO:009019914 | Esophagus | ESCC | regulation of release of cytochrome c from mitochondria | 38/8552 | 48/18723 | 2.11e-06 | 2.43e-05 | 38 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
GO:007122215 | Esophagus | ESCC | cellular response to lipopolysaccharide | 113/8552 | 209/18723 | 8.79e-03 | 3.10e-02 | 113 |
GO:007121617 | Esophagus | ESCC | cellular response to biotic stimulus | 131/8552 | 246/18723 | 9.85e-03 | 3.39e-02 | 131 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLSCR3 | SNV | Missense_Mutation | novel | c.56N>G | p.Pro19Arg | p.P19R | Q9NRY6 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
PLSCR3 | SNV | Missense_Mutation | c.582N>G | p.Phe194Leu | p.F194L | Q9NRY6 | protein_coding | deleterious(0.03) | probably_damaging(0.936) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLSCR3 | SNV | Missense_Mutation | rs776982633 | c.647N>A | p.Cys216Tyr | p.C216Y | Q9NRY6 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-FU-A2QG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PLSCR3 | SNV | Missense_Mutation | rs376916902 | c.617G>A | p.Arg206Gln | p.R206Q | Q9NRY6 | protein_coding | deleterious(0.02) | probably_damaging(0.922) | TCGA-A6-2678-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
PLSCR3 | SNV | Missense_Mutation | c.595G>A | p.Ala199Thr | p.A199T | Q9NRY6 | protein_coding | tolerated(0.12) | possibly_damaging(0.87) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLSCR3 | SNV | Missense_Mutation | c.278N>A | p.Arg93Gln | p.R93Q | Q9NRY6 | protein_coding | deleterious(0.01) | benign(0.297) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
PLSCR3 | SNV | Missense_Mutation | novel | c.337N>T | p.Gly113Trp | p.G113W | Q9NRY6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-3599-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PLSCR3 | SNV | Missense_Mutation | c.229N>A | p.Glu77Lys | p.E77K | Q9NRY6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PLSCR3 | SNV | Missense_Mutation | c.703C>T | p.Arg235Cys | p.R235C | Q9NRY6 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
PLSCR3 | SNV | Missense_Mutation | c.278N>T | p.Arg93Leu | p.R93L | Q9NRY6 | protein_coding | tolerated(1) | benign(0.006) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |